Patient-derived models for the next-gen drug discovery and development
Reduce oncology drug attrition rates
Predict patient response before moving your drug to the clinic
HUB Organoids are unique patient-derived in vitro models developed directly from patient biopsies or resections. Our living tumor biobank includes:
- genetically stable organoid models
- a wide range of carcinoma indications
- matched primary tumor and healthy tissue-derived organoids
- organoids derived from both primary and metastatic lesions
Using HUB´s drug screening platform, clinically-relevant data can be generated that allows you to identify new targets, refine your drug combination strategies, or stratify your patient population with confidence.
Download our fact sheet
Identify responders and non-responders
Prospectively identify your target patient population and investigate the mechanism of response in patients.
Test combination strategies
Identify the most promising combo startegy with the only easily scalable patient-derived in vitro system.
Discover predictive biomarkers
Predict therapeutic outcome using models that recapitulate original patient pathophysiology and preserve patient- and cancer-specific mutations.